@PFDesktop\::ODMA/MHODMA/HBSR05;iManage;501591;1

NSP/KKA/mdm September 27, 2004 PATENT APPLICATION DOCKET NO.: 1767.2011-000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kh

Khalid K. Sadozai, Tamera B. Gooding, Kyle Bui and Charles H. Sherwood

Application No.:

10/743,557

Group Art Unit:

1614

Filed:

December 22, 2003

9128104

Examiner:

Not yet assigned

Confirmation No.:

5063

Title:

CROSSLINKED HYALURONIC ACID COMPOSITIONS FOR TISSUE AUGMENTATION

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:

Typed or printed name of person signing certificate

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

	formation Disclosure Statement is submitted: under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)
[X]	under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

	stage in an international application; or before the mailing date of a first office action on the ments in a non-prov CPA, or a Request for Continued Examination).
[]	under 37 CFR 1.97(c) together with either: [] a Statement under 37 CFR 1.97(e), as checked below, or
	[] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
[]	under 37 CFR 1.97(d) together with: [] a Statement under 37 CFR 1.97(e), as checked below, and [] a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

[] under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

Staten	nent Un	der 37 (CFR 1.97(e)	
[]	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or			
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.			
Staten	nent Un	der 37 (CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000	
[]	comm was no	unication ot receive	Information contained in the Information Disclosure Statement was cited in a on from a foreign patent office in a counterpart application and this communication yed by any individual designated in § 1.56(c) more than thirty days prior to the aformation Disclosure Statement.	
[X]	Enclos	sed here	with is form PTO-1449:	
	[X]	Copies	s of the cited references are enclosed.	
		[]	Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.	
	[]	Applic	s of the cited references are enclosed except those entered in prior application, U.S. cation No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier ation contains copies of the cited references.]	
	[X]	The list	sted references (AN3, AO3, AP3, AQ3 and AU) were cited in the enclosed ational Search Report in a counterpart foreign application.	
	[]	The "c	oncise explanation" requirement (non-English references) for reference(s) [37 CFR 1.98(a)(3) is satisfied by:	
		[]	the explanation provided on the attached sheet.	
		[]	the explanation provided in the Specification.	
		[]	submission of the enclosed International Search Report.	
		[]	submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.	
		[]	the enclosed English language abstract.	

[]	A	pplic	cant requests that the following n	on-published pending appli	cations be considered:
Examir Initia	ner's				
			U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
			U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
			U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
			Examiner	Date	_
	[]	A copy of each above-cited app	olication, including the curre	nt claims, is enclosed.
	[]	A copy of each above-cited app those entered in prior application 35 U.S.C. 120 is claimed.		nt claims, is enclosed, except], to which priority under
The refe	Exan rence	ninei s we	r is requested to return a copy of re considered with the next offic	the above list of pending ap e communication.	plications indicating which
It is	reque	ested	that the information disclosed h	erein be made of record in t	his application.
Met	hod o	of pay	yment:		
[]	A	chec	ck for the fee noted above is encl panying Reply. A copy of this S		cluded in the check with the
[]		lease iclos	charge Deposit Account 08-038 ed.	0 in the amount of \$[. A copy of this Statement is
[X]	Pl	lease	charge any deficiency in fees an	d credit any overpayment to	Deposit Account 08-0380.
			R	Respectfully submitted,	
			H	IAMILTON, BROOK, SMI	TH & REYNOLDS, P.C.
			В	Kraig K. Anderson Registration No.: 54,961 Telephone: (978) 341-0036 Facsimile: (978) 341-0136	

Concord, MA 01742-9133 Dated: Symber 18, 2004

<u> </u>			Silect I C	
PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 1767.2011-000	APPLICATION NO. 10/743,557		
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Khalid K. Sadozai FILING DA December		er 22, 2003	
SEP 3 0 2004 (Use several sheets if necessary)	EXAMINER Not yet assigned	CONFIRMATION NO. 5063	GROUP 1614	

WAD AD	EMARK	F	OREIGN PATENT D	OCUMENTS		
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANS YES	LATION NO
	AN3	WO 02/09792 A1	02/07/2002	Anika Therapeutics, Inc.		
	AO3	WO 94/02517	02/03/1994	Anika Research, Inc.		
	AP3	WO 92/20349	11/26/1992	Genzyme Corporation	1 4	
	AQ3	EP 0 416 250 A2	03/13/1991	The Research Foundation of State University of New York		

•				Officer E of 1
PTO-1449 REPRODUCED			PLICATION NO. 0/743,557	
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Khalid K. Sadozai		FILING DATE December 22, 2003	
September 23, 2004 (Use several sheets if necessary)	EXAMINER Not yet assigned	CONFI 5063	RMATION NO.	GROUP 1614

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AU	Chen, J., et al., "Polysacccharide Hydrogels for Protein Drug Delivery," Carbohydrate Polymers 28 (1995) 69-76.